Copy to clipboard 
Enovis reported 4Q24 orthopedic sales of $287.7 million, up 51.7% compared to the fourth quarter of 2023. For the full year, the company generated $1.06 billion in orthopedic sales, up 53.5% compared to the prior year. On a pro forma basis, Enovis grew 7% in 2024.
The company said its first year of integrating Lima was a huge success, as the legacy company generated over $320 million in 2024 through channel and organizational integrations.
For 2025 and beyond, the company expects additional momentum from key launches like knee revision cones, new shoulder and hip implants and next-gen Arvis applications.
“In terms of cross-selling, there’s a big macro opportunity around our AltiVate shoulder, Empowr Knee and now our great Arvis technology,” said Enovis CEO Matt Trerotola. “Selling those other places around the world is a big opportunity. We’d started a little bit after the Mathys acquisition and now we have more runway after the Lima acquisition. That’s something that’s going to play out over time.”
Enovis expects to focus on completing its Lima acquisition during 2025 but could look for technology and channel bolt-on opportunities.
The company provided 2025 guidance of revenues in the range of $2.19 billion to $2.22 billion, with high-single-digit growth of its recon business.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| 4Q24 | 4Q23 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $232.9 | $148.6 | $84.4 | 56.8% |
| Knees | $54.8 | $32.8 | $22.0 | 67% |
| Hips | $74.0 | $51.8 | $22.2 | 42.8% |
| Extremities | $104.1 | $63.9 | $40.2 | 62.9% |
| Trauma | $30.1 | $17.3 | $12.9 | 74.5% |
| Other | $24.6 | $23.8 | $0.7 | 3.1% |
| Total | $287.7 | $189.7 | $98.0 | 51.7% |
| FY24 | FY23 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $869.4 | $542.2 | $327.2 | 60.4% |
| Knees | $206.7 | $119.8 | $86.9 | 72.6% |
| Hips | $282.7 | $189.1 | $93.6 | 49.5% |
| Extremities | $380.0 | $233.3 | $146.7 | 62.9% |
| Trauma | $104.9 | $63.0 | $41.9 | 66.5% |
| Other | $91.4 | $89.3 | $2.1 | 2.4% |
| Total | $1,065.7 | $694.5 | $371.2 | 53.5% |
Orthopedic Sales by Geography
| 4Q24 | 4Q23 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $145.9 | $128.3 | $17.6 | 13.7% |
| OUS | $141.7 | $61.4 | $80.3 | 130.9% |
| EMEA | $115.1 | $49.3 | $65.7 | 133.3% |
| Asia Pacific | $17.3 | $7.6 | $9.7 | 127.5% |
| Rest of World | $9.4 | $4.5 | $4.9 | 110% |
| Total | $287.7 | $189.7 | $98.0 | 51.7% |
| FY24 | FY23 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $533.7 | $469.5 | $64.2 | 13.7% |
| OUS | $532.0 | $225.0 | $307.1 | 136.5% |
| EMEA | $427.9 | $176.8 | $251.1 | 142.1% |
| Asia Pacific | $65.5 | $28.2 | $37.4 | 132.6% |
| Rest of World | $38.6 | $20.0 | $18.6 | 92.9% |
| Total | $1,065.7 | $694.5 | $371.2 | 53.5% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $561.0 | |
| Cost of Sales | $253.5 | 45.2% |
| Selling and Admin | $257.7 | 45.9% |
| R&D | $24.0 | 9.4% |
| R&D | $24.0 | 9.4% |
| Other | $753.1 | 134.3% |
| Net Earnings | ($703.3) | (125.4%) |
Enovis reported 4Q24 orthopedic sales of $287.7 million, up 51.7% compared to the fourth quarter of 2023. For the full year, the company generated $1.06 billion in orthopedic sales, up 53.5% compared to the prior year. On a pro forma basis, Enovis grew 7% in 2024.
The company said its first year of integrating Lima was a huge success, as...
Enovis reported 4Q24 orthopedic sales of $287.7 million, up 51.7% compared to the fourth quarter of 2023. For the full year, the company generated $1.06 billion in orthopedic sales, up 53.5% compared to the prior year. On a pro forma basis, Enovis grew 7% in 2024.
The company said its first year of integrating Lima was a huge success, as the legacy company generated over $320 million in 2024 through channel and organizational integrations.
For 2025 and beyond, the company expects additional momentum from key launches like knee revision cones, new shoulder and hip implants and next-gen Arvis applications.
“In terms of cross-selling, there’s a big macro opportunity around our AltiVate shoulder, Empowr Knee and now our great Arvis technology,” said Enovis CEO Matt Trerotola. “Selling those other places around the world is a big opportunity. We’d started a little bit after the Mathys acquisition and now we have more runway after the Lima acquisition. That’s something that’s going to play out over time.”
Enovis expects to focus on completing its Lima acquisition during 2025 but could look for technology and channel bolt-on opportunities.
The company provided 2025 guidance of revenues in the range of $2.19 billion to $2.22 billion, with high-single-digit growth of its recon business.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| 4Q24 | 4Q23 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $232.9 | $148.6 | $84.4 | 56.8% |
| Knees | $54.8 | $32.8 | $22.0 | 67% |
| Hips | $74.0 | $51.8 | $22.2 | 42.8% |
| Extremities | $104.1 | $63.9 | $40.2 | 62.9% |
| Trauma | $30.1 | $17.3 | $12.9 | 74.5% |
| Other | $24.6 | $23.8 | $0.7 | 3.1% |
| Total | $287.7 | $189.7 | $98.0 | 51.7% |
| FY24 | FY23 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $869.4 | $542.2 | $327.2 | 60.4% |
| Knees | $206.7 | $119.8 | $86.9 | 72.6% |
| Hips | $282.7 | $189.1 | $93.6 | 49.5% |
| Extremities | $380.0 | $233.3 | $146.7 | 62.9% |
| Trauma | $104.9 | $63.0 | $41.9 | 66.5% |
| Other | $91.4 | $89.3 | $2.1 | 2.4% |
| Total | $1,065.7 | $694.5 | $371.2 | 53.5% |
Orthopedic Sales by Geography
| 4Q24 | 4Q23 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $145.9 | $128.3 | $17.6 | 13.7% |
| OUS | $141.7 | $61.4 | $80.3 | 130.9% |
| EMEA | $115.1 | $49.3 | $65.7 | 133.3% |
| Asia Pacific | $17.3 | $7.6 | $9.7 | 127.5% |
| Rest of World | $9.4 | $4.5 | $4.9 | 110% |
| Total | $287.7 | $189.7 | $98.0 | 51.7% |
| FY24 | FY23 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $533.7 | $469.5 | $64.2 | 13.7% |
| OUS | $532.0 | $225.0 | $307.1 | 136.5% |
| EMEA | $427.9 | $176.8 | $251.1 | 142.1% |
| Asia Pacific | $65.5 | $28.2 | $37.4 | 132.6% |
| Rest of World | $38.6 | $20.0 | $18.6 | 92.9% |
| Total | $1,065.7 | $694.5 | $371.2 | 53.5% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $561.0 | |
| Cost of Sales | $253.5 | 45.2% |
| Selling and Admin | $257.7 | 45.9% |
| R&D | $24.0 | 9.4% |
| R&D | $24.0 | 9.4% |
| Other | $753.1 | 134.3% |
| Net Earnings | ($703.3) | (125.4%) |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
